持续性房颤低压区消融:IDEAL-AF随机临床试验
多中心随机试验纳入209例持续性房颤且低压区≥3.0 cm²的患者,在肺静脉隔离基础上附加个体化低压区消融,12个月无抗心律失常药物下无房性心律失常生存率67.6% vs 37.4%,生活质量和安全性均良好。
要点
- 肺静脉隔离加低压区消融显著提高12个月无心律失常生存率。
- 单次消融后无抗心律失常药物首次复发时间也显著延长。
- 生活质量改善更明显,严重不良事件两组相似。
核心结论
- 在持续性房颤且存在显著低压区的患者中,肺静脉隔离基础上附加低压区消融可改善心律结局和生活质量,且不增加严重不良事件。
研究设计与样本
- 多中心随机临床试验,随访12个月,在5个瑞典消融中心进行。
- 936例首次消融并行电压标测的持续性房颤成人患者中,209例低压区≥3.0 cm²者随机分组。
主要发现
- 主要结局(12个月内1或2次消融后无抗心律失常药物下无房性心律失常)在附加低压区消融组69例(67.6%)vs 单独肺静脉隔离组40例(37.4%),未调整差值30.3%(95%CI 17.4%-43.2%),OR 3.5(95%CI 2.0-6.2),P<.001。
- 单次消融后无抗心律失常药物首次复发时间 favoring 低压区消融(HR 0.4,95%CI 0.3-0.6,P<.001)。
- 低压区消融组健康相关生活质量改善更大,严重不良事件率两组相似。
临床怎么用
- 对持续性房颤且标测到低压区≥3.0 cm²的患者,可考虑在肺静脉隔离基础上附加个体化低压区消融。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pulmonary vein isolation remains the foundational ablation approach for atrial fibrillation (AF), yet outcomes in persistent AF remain suboptimal. Targeting low-voltage zones identified by electroanatomical mapping offers a promising strategy for enhancing ablation success. OBJECTIVE: To determine whether adjunctive individualized low-voltage zone ablation improves arrhythmia outcomes and health-related quality of life beyond pulmonary vein isolation alone in patients with persistent AF and significant low-voltage zones. DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial with 12 months of follow-up conducted at 5 Swedish ablation centers between May 18, 2020, and April 9, 2026. Of 936 adult patients undergoing first-time ablation and voltage mapping for persistent AF, 209 with low-voltage zones of 3.0 cm2 or greater were randomized. INTERVENTIONS: Following pulmonary vein isolation, patients with significant low-voltage zones were randomized to either receive individualized adjunctive low-voltage zone ablation (n = 102) or receive no further ablation (n = 107). MAIN OUTCOMES AND MEASURES: The primary outcome was freedom from documented atrial arrhythmia without antiarrhythmic drugs at 12 months after 1 or 2 ablation procedures within 6 months. Secondary outcomes were time to first recurrence after a single procedure without antiarrhythmic drugs, health-related quality of life, and safety. RESULTS: Among the 209 randomized patients (median age, 72 years; 109 females [52.2%]), the primary outcome was achieved more frequently in the pulmonary vein isolation plus low-voltage zone ablation group than in the pulmonary vein isolation alone group. Arrhythmia-free survival was achieved in 69 patients (67.6%) vs 40 patients (37.4%), respectively (unadjusted difference, 30.3% [95% CI, 17.4%-43.2%]; odds ratio, 3.5 [95% CI, 2.0-6.2]; P < .001). Time to first recurrence after a single ablation procedure without antiarrhythmic drugs also favored low-voltage zone ablation (hazard ratio, 0.4; 95% CI, 0.3-0.6; P < .001). Improvements in health-related quality of life were greater in the low-voltage zone ablation group, whereas rates of serious adverse events were similar between groups. CONCLUSIONS AND RELEVANCE: Adjunctive low-voltage zone ablation added to pulmonary vein isolation improved rhythm outcomes and health-related quality of life without increasing serious adverse events in patients with persistent AF and significant low-voltage zones. These findings support a low-voltage zone-guided ablation strategy in this population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04377594.
引用
- Paul Nordin A, Charitakis E, Carnlöf C, et al. Low-Voltage Ablation in Persistent Atrial Fibrillation: The IDEAL-AF Randomized Clinical Trial. JAMA. 2026. PMID: 42669133. doi:10.1001/jama.2026.17274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。